Laurie Toich, Assistant Editor

FDA-approved weight loss drugs seen to aid weight loss by at least 5%.

Patients receiving Recombinant Factor VIII had an 87% higher chance of developing inhibitors compared with patients receiving plasma-derived therapy.

Survival doubled in patients being treated with nivolumab, but the disease eventually progressed in most patients.

Calcium-targeting drugs could potentially treat fatal cryptococcosis infections.

Salicylic acid was able to suppress the p300 protein and stop leukemia progression.

Research finds patients are fearful of decreasing or stopping medications.

Extremely agitated patients were sedated 12 minutes faster treated with ketamine.

Iso-acoustic focusing could be used to determine how a treatment is working in cancer patients.

Gene therapy found to stop the progression of glioblastoma and high-grade glioma in mouse models.

Researchers discovered that the gene RhoC is able to control how cancer cells create energy and use glutamine.

The Watchman prevents blood clots from forming in the left atrial appendage and prevents strokes.

FCGR2A could indicate which patients with colorectal cancer respond to cetuximab.

Follow-on biologic drug MK-1293 deemed non-inferior to insulin glargine (Lantus).

Patients taking PDE5 inhibitors had a higher risk of melanoma likely due to increased sun exposure.

Macrophages that did not respond to IGF-1 could lead to heart attacks, strokes, or death.

The rate of colorectal cancer is increasing in patients younger than 50-years-old.

Pod-intravaginal rings offered complete protection from new SHIV infections in macaques.

The deletion affects ASGR1’s ability to create a normal structure and function normally.

Top news of the day from across the healthcare landscape.

Certain cancer cells evade the immune system through blocking NLRC5.

Pharmaceutical Care Management Association highlights lowering costs through Medicare Part D and specialty pharmacies.

Nanostructured lipid carriers containing melatonin adjuvant to tamoxifen killed more breast cancer cells than tamoxifen alone.

ACEIs and ARBs lower the risk of stroke and heart attack in patients undergoing peritoneal dialysis by 16%.

Drug labels for canagliflozin and dapagliflozin revised to include acute injury warning.

Drug labels for canagliflozin and dapagliflozin revised to include acute injury warning.

Hyaluronidase could stop elevated pressure in solid tumors, which is a major reason cancer drugs fail.

Differences exist between cancer in males and females on a molecular level.

Top news of the day from across the healthcare landscape.

Premiums for lowest-cost and second-lowest cost silver plans are expected to increase significantly for next year’s Affordable Care Act marketplaces.

Overall improvement in disease activity found in patients with juvenile dermatomyositis receiving anti-TNF therapy.